Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × Afatinib × Clear all

NCT02438722 2026-02-06

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Phase 2/3 Active not recruiting

174 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT06709859 2025-07-17

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02191891 2025-06-25

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

32 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT01853826 2025-04-11

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Phase 3 Completed

481 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT05298176 2025-03-28

COMBINATION

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04206787 2025-02-28

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

72 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT02597946 2025-02-19

Afatinib in NSCLC With HER2 Mutation

Phase 2 Completed

18 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05215548 2025-02-19

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Phase 2 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06759857 2025-01-06

FHND9041

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

NCT04795245 2024-12-27

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

805 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02364609 2024-10-16

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Phase 1 Completed

11 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04750824 2024-09-19

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

110 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT06486142 2024-07-03

ERIS

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04909073 2024-05-17

Observational Study of Afatinib 30 mg Daily

Carcinoma, Non-Small-Cell Lung

NCT01542437 2024-02-06

NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02183883 2023-11-29

DARWIN1

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03727724 2023-10-18

AFACET

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04179890 2023-05-25

UpSwinG

462 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT03827070 2023-04-25

DPTA

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02716311 2022-08-11

ACE-Lung

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03711422 2022-06-14

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Meningeal Neoplasms

NCT02440854 2022-04-27

Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings

80 enrolled 37 charts

Carcinoma, Non-Small-Cell Lung

NCT03054038 2022-04-14

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01156545 2022-04-06

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02747953 2021-03-19

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03157089 2021-02-23

LUX-Lung-IO

Phase 2 Completed

24 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT04448379 2020-12-28

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03370770 2020-12-24

Afatinib Osimertinib Sequencing NIS

204 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04640870 2020-12-23

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Carcinoma, Non-Small-Cell Lung

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT01746251 2020-07-07

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT02514174 2020-03-30

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Phase 4 Completed

25 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02047903 2020-01-09

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

161 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT01953913 2019-08-12

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Phase 3 Completed

542 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Phase 2 Terminated

2 enrolled 8 charts

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT01523587 2019-02-15

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Phase 3 Completed

795 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT01415011 2019-01-15

TIMELY

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02208843 2018-12-17

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase 4 Completed

60 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01121393 2018-12-14

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Phase 3 Completed

364 enrolled 28 charts 2 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT01931306 2018-11-14

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Approved for marketing

Carcinoma, Non-Small-Cell Lung

NCT02131259 2018-09-07

Long-term Observation PMS for Afatinib

1,605 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT02450656 2018-08-27

M14AFS

Phase 1/2 Unknown

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Phase 3 Completed

345 enrolled 23 charts 2 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT01074177 2018-03-09

Understanding Mechanisms of Acquired Resistance to BIBW2992

Phase NA Completed

24 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung